Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to Think About Risk in Myeloma.

Clinical lymphoma, myeloma & leukemia - 1 Aug 2016

Krishnan Amrita

Abstract excerpt

An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bone Marrow
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Hematologic Tests

Share to Hematopoietic Stem Cell Transplantation

Share to Molecular Targeted Therapy

Share to Multiple Myeloma

Source

Identifiers

PMID: 27521310
DOI: 10.1016/j.clml.2016.02.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to Think About Risk in Myeloma.PMID 27521310Read ↗

Deciding on the therapy of multiple myeloma using genetic risk stratification.Semantic proximity Read ↗

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Semantic proximity Read ↗

Integration of Genomics Into Treatment: Are We There Yet?Semantic proximity Read ↗

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted TreatmentSemantic proximity Read ↗

Role of genetics in prognostication in myelomaSemantic proximity Read ↗

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantationSemantic proximity Read ↗

New Targets and New Agents in High-Risk Multiple Myeloma.Semantic proximity Read ↗

Defining and treating high-risk multiple myelomaSemantic proximity Read ↗

V. Molecular classification and risk stratification of myeloma.Semantic proximity Read ↗

Advances in understanding prognosis in myeloma.Semantic proximity Read ↗

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.Semantic proximity Read ↗

Prognostic factors and staging in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.